Inhibition of endogenous activated protein C attenuates experimental autoimmune encephalomyelitis by inducing myeloid-derived suppressor cells

Journal of Immunology

Volumn 191, Issue 7, 2013, Pages 3764-3777

  Alabanza, Leah M ^a   Esmon, Naomi L ^b,c   Esmon, Charles T ^b,c,d   Bynoe, Margaret S ^a  

^a Department of Obstetrics Gynecology   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; CD11B ANTIGEN; CD4 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PC; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELLULAR IMMUNITY; DISEASE SEVERITY; ENZYME INHIBITION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTIC INFILTRATION; MOUSE; NEUROPATHOLOGY; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11B; ARGINASE; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MICE; MICE, TRANSGENIC; MULTIPLE SCLEROSIS; MYELOID CELLS; NITRIC OXIDE SYNTHASE TYPE II; PROTEIN C; REACTIVE OXYGEN SPECIES; T-LYMPHOCYTES, REGULATORY;

EID: 84885151589     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202556     Document Type: Article

References (58)

1. Esmon, C. T. 2012. Protein C anticoagulant system-anti-inflammatory effects. Semin. Immunopathol. 34:127-132.
2. Weiler, H. 2010. Regulation of inflammation by the protein C system. Crit. Care Med. 38 (2, Suppl.) S18-S25.
3. Mosnier, L. O., B. V. Zlokovic, and J. H. Griffin. 2007. The cytoprotective protein C pathway. Blood 109:3161-3172.
4. Van de Wouwer, M., D. Collen, and E. M. Conway. 2004. Thrombomodulinprotein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler. Thromb. Vasc. Biol. 24:1374-1383.
5. Zhou, J., D. Pavlovic, J. Willecke, C. Friedel, S. Whynot, O. Hung, V. Cerny, H. Schroeder, M. Wendt, R. Shukla, and C. Lehmann. 2012. Activated protein C improves pial microcirculation in experimental endotoxemia in rats. Microvas. Res. 83:276-280.
6. Feistritzer, C., and M. Riewald. 2005. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 105:3178-3184.
7. Van Sluis, G. L., T. M. Niers, C. T. Esmon, W. Tigchelaar, D. J. Richel, H. R. Buller, C. J. Van Noorden, and C. A. Spek. 2009. Endogenous activated protein C limits cancer cell extravasation through sphingosine-1-phosphate receptor 1-mediated vascular endothelial barrier enhancement. Blood 114:1968-1973.
8. Pereira, C. P., E. B. Bachli, D. J. Schaer, and G. Schoedon. 2010. Transcriptome analysis revealed unique genes as targets for the anti-inflammatory action of activated protein C in human macrophages. PLoS ONE 5:e15352.
9. Pereira, C., D. J. Schaer, E. B. Bachli, M. O. Kurrer, and G. Schoedon. 2008. Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the antiinflammatory action of activated protein C and interleukin-10. Arterioscler. Thromb. Vasc. Biol. 28:504-510.
10. White, B., M. Schmidt, C. Murphy, W. Livingstone, D. O'Toole, M. Lawler, L. O'Neill, D. Kelleher, H. P. Schwarz, and O. P. Smith. 2000. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br. J. Haematol. 110:130-134.
11. Yuksel, M., K. Okajima, M. Uchiba, S. Horiuchi, and H. Okabe. 2002. Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes. Thromb. Haemost. 88:267-273.
12. Joyce, D. E., L. Gelbert, A. Ciaccia, B. De Hoff, and B. W. Grinnell. 2001. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J. Biol. Chem. 276:11199-11203.
13. Stephenson, D. A., L. J. Toltl, S. Beaudin, and P. C. Liaw. 2006. Modulation of monocyte function by activated protein C, a natural anticoagulant. J. Immunol. 177:2115-2122.
14. Shua, F., H. Kobayashia, K. Fukudomeb, N. Tsuneyoshib, M. Kimotob, and T. Teraoa. 2000. Activated protein C suppresses tissue factor expression on U937 cells in the endothelial protein C receptor-dependent manner. FEBS Lett. 477:208-212.
15. Cao, C., Y. Gao, Y. Li, T. M. Antalis, F. J. Castellino, and L. Zhang. 2010. The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b. J. Clin. Invest. 120:1971-1980.
16. Bernard, G. R., J. L. Vincent, P. F. Laterre, S. P. La Rosa, J. F. Dhainaut, A. Lopez-Rodriguez, J. S. Steingrub, G. E. Garber, J. D. Helterbrand, E. W. Ely, and C. J. Fisher, Jr.; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. 2001. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344:699-709.
17. Ranieri, V. M., B. T. Thompson, P. S. Barie, J. F. Dhainaut, I. S. Douglas, S. Finfer, B. Gårdlund, J. C. Marshall, A. Rhodes, A. Artigas, et al; PROWESS-SHOCK Study Group. 2012. Drotrecogin alfa (activated) in adults with septic shock. N. Engl. J. Med. 366:2055-2064.
18. Vincent, J. L. 2012. The rise and fall of drotrecogin alfa (activated). Lancet Infect. Dis. 12:649-651.
19. Shibata, M., S. R. Kumar, A. Amar, J. A. Fernandez, F. Hofman, J. H. Griffin, and B. V. Zlokovic. 2001. Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation 103:1799-1805.
20. Zhong, Z., H. Ilieva, L. Hallagan, R. Bell, I. Singh, N. Paquette, M. Thiyagarajan, R. Deane, J. A. Fernandez, S. Lane, et al. 2009. Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J. Clin. Invest. 119:3437-3449.
21. Scaldaferri, F., M. Sans, S. Vetrano, C. Graziani, R. De Cristofaro, B. Gerlitz, A. Repici, V. Arena, A. Malesci, J. Panes, et al. 2007. Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. J. Clin. Invest. 117:1951-1960.
22. Yasui, H., E. C. Gabazza, S. Tamaki, T. Kobayashi, O. Hataji, H. Yuda, S. Shimizu, K. Suzuki, Y. Adachi, and O. Taguchi. 2001. Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse. Am. J. Respir. Crit. Care Med. 163:1660-1668.
23. McFarland, H. F., and R. Martin. 2007. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 8:913-919.
24. Gold, R., C. Linington, and H. Lassmann. 2006. Understanding pathogenesis and therapy of multiple sclerosis via animal models:70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129:1953-1971.
25. Batoulis, H., K. Addicks, and S. Kuerten. 2010. Emerging concepts in autoimmune encephalomyelitis beyond the CD4/T (H) 1 paradigm. Ann. Anat. 192:179-193.
26. Han, M. H., S. I. Hwang, D. B. Roy, D. H. Lundgren, J. V. Price, S. S. Ousman, G. H. Fernald, B. Gerlitz, W. H. Robinson, S. E. Baranzini, et al. 2008. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 451:1076-1081.
27. Koh, C. S., J. Gausas, and P. Y. Paterson. 1993. Neurovascular permeability and fibrin deposition in the central neuraxis of Lewis rats with cell-transferred experimental allergic encephalomyelitis in relationship to clinical and histopathological features of the disease. J. Neuroimmunol. 47:141-145.
28. Inaba, Y., M. Ichikawa, A. Inoue, M. Itoh, M. Kyogashima, Y. Sekiguchi, S. Nakamura, A. Komiyama, and C. Koh. 2001. Plasma thrombin-antithrombin III complex is associated with the severity of experimental autoimmune encephalomyelitis. J. Neurol. Sci. 185:89-93.
29. Condamine, T., and D. I. Gabrilovich. 2011. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 32:19-25.
30. Xu, J., Y. Ji, X. Zhang, M. Drake, and C. T. Esmon. 2009. Endogenous activated protein C signaling is critical to protection of mice from lipopolysaccarideinduced septic shock. J. Thromb. Haemost. 7:851-856.
31. Corraliza, I. M., M. L. Campo, G. Soler, and M. Modolell. 1994. Determination of arginase activity in macrophages: a micromethod. J. Immunol. Methods 174:231-235.
32. Grisham, M. B., and T. Yamada. 1992. Neutrophils, nitrogen oxides, and inflammatory bowel disease. Ann. N. Y. Acad. Sci. 664:103-115.
33. Gareau, P. J., A. C. Wymore, G. P. Cofer, and G. A. Johnson. 2002. Imaging inflammation: direct visualization of perivascular cuffing in EAE by magnetic resonance microscopy. J. Magn. Reson. Imaging 16:28-36.
34. Sabat, R., G. Grütz, K. Warszawska, S. Kirsch, E. Witte, K. Wolk, and J. Geginat. 2010. Biology of interleukin-10. Cytokine Growth Factor Rev. 21:331-344.
35. Brown, D. A., and P. E. Sawchenko. 2007. Time course and distribution of inflammatory and neurodegenerative events suggest structural bases for the pathogenesis of experimental autoimmune encephalomyelitis. J. Comp. Neurol. 502:236-260.
36. Mills, J. H., D. G. Kim, A. Krenz, J. F. Chen, and M. S. Bynoe. 2012. A2A adenosine receptor signaling in lymphocytes and the central nervous system regulates inflammation during experimental autoimmune encephalomyelitis. J. Immunol. 188:5713-5722.
37. Ercolini, A. M., and S. D. Miller. 2006. Mechanisms of immunopathology in murine models of central nervous system demyelinating disease. J. Immunol. 176:3293-3298.
38. Montero, A. J., C. M. Diaz-Montero, C. E. Kyriakopoulos, V. Bronte, and S. Mandruzzato. 2012. Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J. Immunother. 35:107-115.
39. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9:162-174.
40. Cripps, J. G., and J. D. Gorham. 2011. MDSC in autoimmunity. Int. Immunopharmacol. 11:789-793.
41. Zea, A. H., P. C. Rodriguez, K. S. Culotta, C. P. Hernandez, J. De Salvo, J. B. Ochoa, H. J. Park, J. Zabaleta, and A. C. Ochoa. 2004. L-Arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes. Cell. Immunol. 232:21-31.
42. O'Brien, L. A., M. A. Richardson, S. F. Mehrbod, D. T. Berg, B. Gerlitz, A. Gupta, and B. W. Grinnell. 2007. Activated protein C decreases tumor necrosis factor related apoptosis-inducing ligand by an EPCR-independent mechanism involving Egr-1/Erk-1/2 activation. Arterioscler. Thromb. Vasc. Biol. 27:2634-2641.
43. Toltl, L. J., S. Beaudin, and P. C. Liaw; Canadian Critical Care Translational Biology Group. 2008. Activated protein C up-regulates IL-10 and inhibits tissue factor in blood monocytes. J. Immunol. 181:2165-2173.
44. Sonda, N., M. Chioda, S. Zilio, F. Simonato, and V. Bronte. 2011. Transcription factors in myeloid-derived suppressor cell recruitment and function. Curr. Opin. Immunol. 23:279-285.
45. Yang, X. V., Y. Banerjee, J. A. Fernández, H. Deguchi, X. Xu, L. O. Mosnier, R. T. Urbanus, P. G. de Groot, T. C. White-Adams, O. J. McCarty, and J. H. Griffin. 2009. Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells. Proc. Natl. Acad. Sci. USA 106:274-279.
46. Zhu, B., Y. Bando, S. Xiao, K. Yang, A. C. Anderson, V. K. Kuchroo, and S. J. Khoury. 2007. CD11b+Ly-6C (hi) suppressive monocytes in experimental autoimmune encephalomyelitis. J. Immunol. 179:5228-5237.
47. Moliné-Velázquez, V., H. Cuervo, V. Vila-Del Sol, M. C. Ortega, D. Clemente, and F. de Castro. 2011. Myeloid-derived suppressor cells limit the inflammation by promoting T lymphocyte apoptosis in the spinal cord of a murine model of multiple sclerosis. Brain Pathol. 21:678-691.
48. Rodriguez, P. C., D. G. Quiceno, and A. C. Ochoa. 2007. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 109:1568-1573.
49. Rodriguez, P. C., A. H. Zea, J. De Salvo, K. S. Culotta, J. Zabaleta, D. G. Quiceno, J. B. Ochoa, and A. C. Ochoa. 2003. L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J. Immunol. 171:1232-1239.
50. Bingisser, R. M., P. A. Tilbrook, P. G. Holt, and U. R. Kees. 1998. Macrophagederived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J. Immunol. 160:5729-5734.
51. Hoechst, B., L. A. Ormandy, M. Ballmaier, F. Lehner, C. Krüger, M. P. Manns, T. F. Greten, and F. Korangy. 2008. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4 (+) CD25 (+) Foxp3 (+) T cells. Gastroenterology 135:234-243.
52. Huang, B., P. Y. Pan, Q. Li, A. I. Sato, D. E. Levy, J. Bromberg, C. M. Divino, and S. H. Chen. 2006. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66:1123-1131.
53. Serafini, P., S. Mgebroff, K. Noonan, and I. Borrello. 2008. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 68:5439-5449.
54. Chalmin, F., S. Ladoire, G. Mignot, J. Vincent, M. Bruchard, J. P. Remy-Martin, W. Boireau, A. Rouleau, B. Simon, D. Lanneau, et al. 2010. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J. Clin. Invest. 120:457-471.
55. Wu, L., H. Du, Y. Li, P. Qu, and C. Yan. 2011. Signal transducer and activator of transcription 3 (Stat3C) promotes myeloid-derived suppressor cell expansion and immune suppression during lung tumorigenesis. Am. J. Pathol. 179:2131-2141.
56. Kuerten, S., and P. V. Lehmann. 2011. The immune pathogenesis of experimental autoimmune encephalomyelitis: lessons learned for multiple sclerosis? J. Interferon Cytokine Res. 31:907-916.
57. Recks, M. S., K. Addicks, and S. Kuerten. 2011. Spinal cord histopathology of MOG peptide 35-55-induced experimental autoimmune encephalomyelitis is time-and score-dependent. Neurosci. Lett. 494:227-231.
58. Vajkoczy, P., M. Laschinger, and B. Engelhardt. 2001. Alpha4-integrin-VCAM-1 binding mediates G protein-independent capture of encephalitogenic T cell blasts to CNS white matter microvessels. J. Clin. Invest. 108:557-565.